Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase 1a/b Study of MTL-CEBPA in Combination With a PD-1 Inhibitor (Pembrolizumab) in Adult Patients With Advanced Solid Tumours

NCT04105335 is registered in ClinicalTrials.gov with Mina Alpha Limited as lead sponsor.

NCT NCT04105335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04105335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase 1a/b Study of MTL-CEBPA in Combination With a PD-1 Inhibitor (Pembrolizumab) in Adult Patients With Advanced Solid Tumours
Lead sponsor
Mina Alpha Limited
Phase
Phase 1
Overall status
Completed
Start date
November 13, 2019
Completion date
January 25, 2025
Enrollment
50 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult